The Journal of Neuropsychiatry and Clinical Neurosciences
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Panagiotis, B.
* Search for Related Content
PubMed
* Articles by Panagiotis, B.
Related Collections
* Schizophrenia Spectrum Disorders
* Other Neuroleptics
J Neuropsychiatry Clin Neurosci 11:117-118, February 1999
© 1999 American Psychiatric Press, Inc.


Letter

Grand Mal Seizures With Liver Toxicity in a Case of Clozapine Treatment

Bakaras Panagiotis, M.D., Arta, Greece

Key Words: Clozapine • Side Effects • Seizures

SIR: There are several reports in the literature that seizures, EEG changes, and severe liver toxicity are associated with clozapine treatment, suggesting a need for routine monitoring of liver function.15 We report a case where seizures and serious liver toxicity necessitated discontinuation of clozapine.

Case Report
A 30-year-old man with schizophrenic psychosis was treated with clozapine because of failure of other antipsychotic medications and severe extrapyramidal side effects. EEG, liver enzymes, and CT scan were normal before treatment, and there was no history of brain damage, epilepsy, or liver disease. He was put on clozapine (monotherapy), which was gradually increased to 400 mg in the course of the first 3 weeks of treatment. In the fourth week of treatment the patient presented a grand mal attack, and clozapine was reduced to 300 mg. Nine days later, EEG showed generalized theta activity and slow paroxysmal waves with spikes focused on the left parietal region. Five days after the seizures, liver enzymes, which were tested every week and had been normal the week before, were greatly increased: AST=116 iv/L (normal value <40), ALT=215 (n.v. <40), GGT=167 (n.v. <52), alkaline phosphatase=318 (n.v. <310). The first three enzymes were 3 to 5 times above normal level. EEG was also normal 5 weeks later.

In this case, the patient manifested severe liver toxicity that did not allow continuation of clozapine treatment, and he had epileptic activity with abnormal EEG (focused on the left parietal region, but these changes usually occur bilaterally1) in the fourth week of treatment with 400 mg clozapine.4,5 This case lends support to the worthwhile suggestion that liver function tests be performed routinely with clozapine treatment.3,6

REFERENCES

  1. Welch J, Maschreck J, Redmond D: Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6:250–256[Abstract/Free Full Text]
  2. Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacology 1989; 99:S97–S100
  3. Kellner M, Wiedemann K, Krieg JC, et al: Toxic hepatitis by clozapine treatment (letter). Am J Psychiatry 1993; 150:985–986
  4. Thatcher GW, Gates M, Bour B: Clozapine-induced toxic hepatitis (letter). Am J Psychiatry 1995; 152:296–297
  5. Worrall R, Wilson A, Gullen M: Dystonia and drug-induced hepatitis in a patient treated with clozapine (letter). Am J Psychiatry 1995; 152:647–648
  6. Merikangas J: Routine tests of drugs (letter). Am J Psychiatry 1991; 148:947




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Panagiotis, B.
* Search for Related Content
PubMed
* Articles by Panagiotis, B.
Related Collections
* Schizophrenia Spectrum Disorders
* Other Neuroleptics


Get information about faster international access.

Privacy Policy

Copyright © 1999 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Neuropsychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org